1-Hydroxybenzotriazole → 2-(1,3-Dimethyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-5-yl)-N-[4-(trifluoromethyl)-1,3-thiazol-2-yl]acetamide

HRID 877026ノート

反応式

HRID 877026 の反応式
[CH3:1][N:2]1[C:7]2=[CH:8][S:9][C:10](C)=[C:6]2[C:5](=[O:12])[N:4]([CH3:13])[C:3]1=[O:14].[F:15][C:16]([F:24])([F:23])[C:17]1[N:18]=[C:19]([NH2:22])[S:20][CH:21]=1.CCN=C=NC[CH2:31][CH2:32]N(C)C.Cl.C1C=CC2N([OH:46])N=NC=2C=1>CN(C1C=CN=CC=1)C.ClCCCl>[CH3:1][N:2]1[C:10]2[S:9][CH:8]=[C:7]([CH2:31][C:32]([NH:22][C:19]3[S:20][CH:21]=[C:17]([C:16]([F:24])([F:23])[F:15])[N:18]=3)=[O:46])[C:6]=2[C:5](=[O:12])[N:4]([CH3:13])[C:3]1=[O:14]

参加物

7

実験手順

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 1 (100 mg, 0.393 mmol) with 4-(trifluoromethyl)-1,3-thiazol-2-amine (66 mg, 0.393 mmol) in the presence of EDCI hydrochloride (90 mg, 0.471 mmol), HOBt (16 mg, 0.118 mmol) and DMAP (5 mg, 0.039 mmol) in 1,2 dichloroethane (4 ml) to give 27 mg of the product as a white solid; 1H NMR (300 MHz, DMSO-d6) δ 3.18 (s, 3H), 3.46 (s, 3H), 4.05 (s, 2H), 7.07 (s, 1H), 7.91 (s, 1H), 12.70 (br s, 1H); APCI-MS (m/z) 404.97 (M+H)+.

出典と根拠

ORDレコード
ord-f2f002be385c43dab5743f6b12e5841b
出典データセット
uspto-grants-2015_03
特許番号
US08987278B2

反応ノート

読み込み中…